Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Operating Leases (2023 - 2025)

Beta Bionics (BBNX) has disclosed Operating Leases for 3 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 6.3% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Dec 2025, down 6.3% year-over-year, with the annual reading at $5.4 million for FY2025, 6.3% down from the prior year.
  • Operating Leases hit $5.4 million in Q4 2025 for Beta Bionics, down from $5.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.7 million in Q4 2024 to a low of $3.0 million in Q4 2023.
  • Historically, Operating Leases has averaged $5.1 million across 3 years, with a median of $5.4 million in 2025.
  • Biggest five-year swings in Operating Leases: soared 90.93% in 2024 and later fell 6.3% in 2025.
  • Year by year, Operating Leases stood at $3.0 million in 2023, then skyrocketed by 90.93% to $5.7 million in 2024, then dropped by 6.3% to $5.4 million in 2025.
  • Business Quant data shows Operating Leases for BBNX at $5.4 million in Q4 2025, $5.7 million in Q3 2025, and $5.2 million in Q2 2025.